Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-Solidarity Trial
NCT04321616Phase 3Unknown
- Sponsor
- Oslo University Hospital
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine and remdesivir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Oslo University Hospital. Primary endpoint: In-hospital mortality at 3 weeks. Status: unknown.
02
Drugs
hydroxychloroquineremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04321616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321616.